324 related articles for article (PubMed ID: 8128561)
1. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63.
van der Leek ML; Feller JA; Sorensen G; Isaacson W; Adams CL; Borde DJ; Pfeiffer N; Tran T; Moyer RW; Gibbs EP
Vet Rec; 1994 Jan; 134(1):13-8. PubMed ID: 8128561
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs.
Mengeling WL; Brockmeier SL; Lager KM
Arch Virol; 1994; 134(3-4):259-69. PubMed ID: 8129615
[TBL] [Abstract][Full Text] [Related]
3. Level of virulent virus excreted by infected pigs previously vaccinated with different glycoprotein deleted Aujeszky's disease vaccines.
Vannier P; Hutet E; Bourgueil E; Cariolet R
Vet Microbiol; 1991 Nov; 29(3-4):213-23. PubMed ID: 1663287
[TBL] [Abstract][Full Text] [Related]
4. Safety of an Aujeszky's disease vaccine based on deletion mutant strain 783 which does not express thymidine kinase and glycoprotein I.
van Oirschot JT; Terpstra C; Moormann RJ; Berns AJ; Gielkens AL
Vet Rec; 1990 Nov; 127(18):443-6. PubMed ID: 2177288
[TBL] [Abstract][Full Text] [Related]
5. Potency of an experimental DNA vaccine against Aujeszky's disease in pigs.
Gerdts V; Jöns A; Mettenleiter TC
Vet Microbiol; 1999 Mar; 66(1):1-13. PubMed ID: 10223318
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity in Aujeszky's disease virus structural glycoprotein gVI (gp50) in swine.
Mukamoto M; Watanabe I; Kobayashi Y; Icatlo FC; Ishii H; Kodama Y
Vet Microbiol; 1991 Oct; 29(2):109-21. PubMed ID: 1660638
[TBL] [Abstract][Full Text] [Related]
7. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines.
Peeters B; Bouma A; de Bruin T; Moormann R; Gielkens A; Kimman T
Vaccine; 1994 Mar; 12(4):375-80. PubMed ID: 8178562
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses.
Brockmeier SL; Lager KM; Tartaglia J; Riviere M; Paoletti E; Mengeling WL
Vet Microbiol; 1993 Dec; 38(1-2):41-58. PubMed ID: 8128602
[TBL] [Abstract][Full Text] [Related]
9. Extent and duration of virulent virus excretion upon challenge of pigs vaccinated with different glycoprotein-deleted Aujeszky's disease vaccines.
Pensaert MB; De Smet K; De Waele K
Vet Microbiol; 1990 Apr; 22(2-3):107-17. PubMed ID: 2162094
[TBL] [Abstract][Full Text] [Related]
10. A novel concept for the control of Aujeszky's disease: experiences in two vaccinated pig herds.
van Oirschot JT; Wijsmuller JM; de Waal CA; van Lith PM
Vet Rec; 1990 Feb; 126(7):159-63. PubMed ID: 2155499
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.
Marchioli CC; Yancey RJ; Petrovskis EA; Timmins JG; Post LE
J Virol; 1987 Dec; 61(12):3977-82. PubMed ID: 2824827
[TBL] [Abstract][Full Text] [Related]
12. Intranasal vaccination of pigs against Aujeszky's disease: comparison with one or two doses of attenuated vaccines in pigs with high maternal antibody titres.
Van Oirschot JT
Res Vet Sci; 1987 Jan; 42(1):12-6. PubMed ID: 3029845
[TBL] [Abstract][Full Text] [Related]
13. Constancy of Aujeszky's field virus antibody titres in sows repeatedly vaccinated with a gI-negative vaccine.
Hopp W; Jungblut R
Acta Vet Hung; 1994; 42(2-3):409-11. PubMed ID: 7810439
[TBL] [Abstract][Full Text] [Related]
14. Influence of vaccination route on the efficacy of Aujeszky's disease deletion-mutant vaccine.
Hasebe H; Osorio FA; Hogg A; Liauw H; Bartkoski MJ; Sugiyama M
J Vet Med Sci; 1992 Aug; 54(4):693-8. PubMed ID: 1327180
[TBL] [Abstract][Full Text] [Related]
15. Oronasal challenge of fattening pigs after vaccination with an inactivated Aujeszky's disease vaccine.
Pensaert MB; Vandeputte J; Andries K
Res Vet Sci; 1982 Jan; 32(1):12-6. PubMed ID: 6283610
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the protective efficacy of Aujeszky's disease (pseudorabies) virus glycoproteins obtained from different sources.
Puentes E; Eiras A; Cancio E; Nores MV; Aguilera A; Seoane R; Regueiro BJ
Vet Microbiol; 1993 May; 35(1-2):45-59. PubMed ID: 8395745
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of serum antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive enzyme immunoassay.
van Oirschot JT; Rziha HJ; Moonen PJ; Pol JM; van Zaane D
J Gen Virol; 1986 Jun; 67 ( Pt 6)():1179-82. PubMed ID: 3011974
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an intranasal immunization with gEgC and gEgI double-deletion mutants of Aujeszky's disease virus in maternally immune pigs and the effects of a successive intramuscular booster with commercial vaccines.
Nauwynck HJ; Labarque GG; Pensaert MB
Zentralbl Veterinarmed B; 1999 Dec; 46(10):713-22. PubMed ID: 10676150
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of three doses of the genetically engineered Aujeszky's disease virus vaccine strain 783 in pigs with maternal antibodies.
Kimman TG
Vaccine; 1992; 10(6):363-5. PubMed ID: 1317982
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of specific humoral immune response in pigs vaccinated intradermally with deleted Aujeszky's disease vaccine and challenged with virulent strain of Herpesvirus suis type 1.
Mikulska-Skupień E; Szweda W; Procajło Z
Pol J Vet Sci; 2005; 8(1):11-6. PubMed ID: 15794468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
